Skip Navigation LinksHome > May 2013 - Volume 35 - Issue 4 > Transient Effect of Anti-CD20 Therapy in a Child With 22q11....
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0b013e31828be602
Clinical and Laboratory Observations

Transient Effect of Anti-CD20 Therapy in a Child With 22q11.2 Deletion Syndrome and Severe Steroid Refractory Cytopenias: A Case Report

Soldatou, Alexandra MD, PhD*; Anastassiou, Theodora MD, PhD; Vougiouka, Olga MD, PhD*; Goussetis, Evgenios MD, PhD; Kossiva, Lydia MD, PhD*

Collapse Box

Abstract

We report on the development of steroid-refractory recurrent cytopenias in a child with 22q11.2 deletion syndrome. His first hematological complication was autoimmune hemolytic anemia at 3 months of age. Thereafter, he developed severe autoimmune cytopenias of all 3 hematological lineages with poor response to steroids and intravenous immunoglobulin. At the age of 2½ years, a course of anti-CD20 therapy (Rituximab) was given with transient hematological recovery. Because of persistent symptoms, bone marrow transplantation from a matched unrelated donor was performed. Although the data in the use of anti-CD20 therapy in children with 22q11.2 deletion syndrome and autoimmune cytopenias are limited, our experience suggests its potential benefit.

© 2013 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/JPHOonline

For additional oncology content, visit LWW Oncology Journals on Facebook.